Literature DB >> 25271110

Blockade of co-stimulation in chronic inflammatory diseases.

Clemens Scheinecker1.   

Abstract

Costimulatory molecules are key elements in T cell activation. Therapeutic inhibition of costimulatory pathways have been recognized as valid therapeutic strategies in the treatment of various inflammatory diseases. This article will describe their mechanisms of action and will summarize the results from clinical trials in the field of rheumatologic diseases.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25271110     DOI： 10.1007/s10354-014-0313-x

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN： 0043-5341


  40 in total

Review 1.  The regulation of lymphocyte activation by inhibitory receptors.

Authors:  Paul J Leibson
Journal:  Curr Opin Immunol       Date:  2004-06       Impact factor: 7.486

2.  Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.

Authors:  Ronald F van Vollenhoven; Roy Fleischmann; Stanley Cohen; Eun Bong Lee; Juan A García Meijide; Sylke Wagner; Sarka Forejtova; Samuel H Zwillich; David Gruben; Tamas Koncz; Gene V Wallenstein; Sriram Krishnaswami; John D Bradley; Bethanie Wilkinson
Journal:  N Engl J Med       Date:  2012-08-09       Impact factor: 91.245

3.  Prophylactic administration of abatacept prevents disease and bone destruction in a rat model of collagen-induced arthritis.

Authors:  C Kliwinski; D Kukral; J Postelnek; B Krishnan; L Killar; A Lewin; S Nadler; R Townsend
Journal:  J Autoimmun       Date:  2005-10-25       Impact factor: 7.094

4.  Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2.

Authors:  L M Webb; M J Walmsley; M Feldmann
Journal:  Eur J Immunol       Date:  1996-10       Impact factor: 5.532

5.  Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial.

Authors:  Joel M Kremer; Maxime Dougados; Paul Emery; Patrick Durez; Jean Sibilia; William Shergy; Serge Steinfeld; Elizabeth Tindall; Jean-Claude Becker; Tracy Li; Isaac F Nuamah; Richard Aranda; Larry W Moreland
Journal:  Arthritis Rheum       Date:  2005-08

6.  Abatacept (CTLA-4IG) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis.

Authors:  M Bonelli; E Ferner; L Göschl; S Blüml; A Hladik; T Karonitsch; H P Kiener; R Byrne; B Niederreiter; C W Steiner; E Rath; M Bergmann; J S Smolen; C Scheinecker
Journal:  Arthritis Rheum       Date:  2013-03

7.  Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.

Authors:  Nicolino Ruperto; Daniel J Lovell; Pierre Quartier; Eliana Paz; Nadina Rubio-Pérez; Clovis A Silva; Carlos Abud-Mendoza; Ruben Burgos-Vargas; Valeria Gerloni; Jose A Melo-Gomes; Claudia Saad-Magalhães; Flavio Sztajnbok; Claudia Goldenstein-Schainberg; Morton Scheinberg; Immaculada Calvo Penades; Michael Fischbach; Javier Orozco; Philip J Hashkes; Christine Hom; Lawrence Jung; Loredana Lepore; Sheila Oliveira; Carol A Wallace; Leonard H Sigal; Alan J Block; Allison Covucci; Alberto Martini; Edward H Giannini
Journal:  Lancet       Date:  2008-07-14       Impact factor: 79.321

8.  Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.

Authors:  P Waterhouse; J M Penninger; E Timms; A Wakeham; A Shahinian; K P Lee; C B Thompson; H Griesser; T W Mak
Journal:  Science       Date:  1995-11-10       Impact factor: 47.728

Review 9.  T-cell co-stimulatory pathways in autoimmunity.

Authors:  Jörg J Goronzy; Cornelia M Weyand
Journal:  Arthritis Res Ther       Date:  2008-10-15       Impact factor: 5.156

10.  Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate.

Authors:  M Schiff; M Keiserman; C Codding; S Songcharoen; A Berman; S Nayiager; C Saldate; T Li; R Aranda; J-C Becker; C Lin; P L N Cornet; M Dougados
Journal:  Ann Rheum Dis       Date:  2007-11-29       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.